Domestic Markets To Boost Pharma Sector Growth, Says KRChoksey
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Pharma companies are expected to continue their stellar performance in Q3 FY21, after recovering from Covid-19 driven disruptions in previous quarters.
Q2 FY21 management commentary suggested robust growth opportunities from U.S. and other export markets for Indian pharma companies, along with opportunities arising from Covid-19 related challenges in the Indian Market.
New product approval from U.S. Food and Drug administration is expected to further fuel the growth trajectory of Indian Pharma Companies.
For Q3 FY21, we expect our coverage universe to post 12.3% YoY growth in sales.
From our coverage universe, we expect all the pharma companies to report growth in their operating metrics.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.